BioXcel Therapeutics (BTAI) Q2 2024 earnings summary

Executive summary

• IGALMI net revenue increased 141% year-over-year to $1.1M in Q2 2024, driven by new contracts and increased utilization in psychiatric and behavioral health clinics.

• Operating expenses declined sharply due to strategic reprioritization, workforce reductions, and lower commercialization costs, with annualized operating expenses expected to be reduced by $80M.

• BXCL501 clinical programs are advancing, including pivotal Phase 3 SERENITY At-Home and TRANQUILITY In-Care trials for agitation in bipolar, schizophrenia, and Alzheimer's, with FDA Breakthrough Therapy Designation for Alzheimer's agitation.

• Strengthened IP portfolio with a new IGALMI patent allowance, expected to extend protection to 2043.

• Management has identified substantial doubt about the ability to continue as a going concern beyond 12 months without additional capital.

Financial highlights

• Q2 2024 net revenue: $1.1M, up 141% year-over-year and 90% sequentially; six-month revenue: $1.7M, up from $663K year-over-year.

• R&D expenses fell to $8.0M in Q2 2024 from $27.0M in Q2 2023, reflecting trial wind-downs and lower personnel costs.

• SG&A expenses dropped to $9.5M in Q2 2024 from $25.9M in Q2 2023, due to reprioritization and reduced commercialization costs.

• Net loss narrowed to $8.3M in Q2 2024 from $53.5M in Q2 2023, aided by unrealized gains on derivative liabilities.

• Cash and cash equivalents totaled $56.3M as of June 30, 2024; cash runway expected through end of 2024.

Outlook and guidance

• SERENITY At-Home pivotal Phase 3 trial is ready for initiation, with protocol aligned with FDA feedback and CMC work completed.

• TRANQUILITY In-Care protocol finalized and pending agency submission; cost expectations unchanged.

• Progression of key clinical trials is contingent on securing further capital; at least $20M must be raised by November 30, 2024, to avoid default under the Credit Agreement.

• Management is pursuing equity sales, partnerships, and cost reductions to improve liquidity and fund late-stage trials.

• No specific timing for data readouts or trial enrollment provided, but SERENITY is expected to be less complex and faster to execute.